Veru Inc. (NASDAQ:VERU) Director Acquires $52,403.45 in Stock

Veru Inc. (NASDAQ:VERU) Director Michael L. Rankowitz acquired 95,279 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were bought at an average cost of $0.55 per share, for a total transaction of $52,403.45. Following the transaction, the director now owns 195,279 shares of the company’s stock, valued at $107,403.45. This represents a 95.28 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Veru Price Performance

Shares of NASDAQ:VERU opened at $0.57 on Friday. The firm has a market capitalization of $83.83 million, a P/E ratio of -2.20 and a beta of -0.54. The business’s 50-day moving average is $0.70 and its 200 day moving average is $0.75. Veru Inc. has a 1 year low of $0.47 and a 1 year high of $1.92.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. Veru had a negative net margin of 223.85% and a negative return on equity of 112.75%. On average, analysts expect that Veru Inc. will post -0.22 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Veru in a research report on Thursday, January 2nd. Oppenheimer reissued an “outperform” rating and set a $5.00 target price on shares of Veru in a research report on Tuesday, November 5th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Barclays PLC increased its position in shares of Veru by 309.2% in the 3rd quarter. Barclays PLC now owns 184,777 shares of the company’s stock valued at $142,000 after acquiring an additional 139,617 shares during the period. State Street Corp grew its stake in Veru by 4.3% during the 3rd quarter. State Street Corp now owns 2,072,065 shares of the company’s stock valued at $1,593,000 after purchasing an additional 84,483 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Veru by 4.7% in the third quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company’s stock valued at $2,261,000 after purchasing an additional 131,720 shares during the period. Jane Street Group LLC raised its stake in shares of Veru by 142.8% in the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock worth $74,000 after purchasing an additional 56,736 shares during the last quarter. Finally, Gladstone Institutional Advisory LLC lifted its holdings in shares of Veru by 34.2% during the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock worth $44,000 after purchasing an additional 14,500 shares during the period. Hedge funds and other institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.